RE:RE:RE:RE:RE:RE:RE:Questions relating to WarrantsIt is the responsibility of management and directors to assess what is the best action to take for shareholders, it is called fiduciary responsibility.
I have no idea what the majority of shareholders think or feel about the slow pace of progress and recurring glitches but I sense that this group of execs appears to be in over their heads. Recent Ph2 floundering and repeated capital raising amatuer moves does not earn high marks.
This needs to be taken as a sign of weakness and absence of the skills needed to achieve success.
I don't advocate wholesale changes at the top yet, they need help and any new blood will need time to absorb matters and establish relationships.
I expect there are several heavyweight potential JV partners who could bring the savvy needed to get this great science into play commercially. They would know quickly which staff to eliminate or replace and who the contributors are.
The prime investment bankers most likely see the opportunity and may have already weighed in. Why not get RBC, or another, to run around the bases and get a sense for what execution JV entity may be out there for consideration. Weigh in then on a deal that protects the current TLT investors who own the technology.
That's a better approach than permitting the current leadership to continue to stumble around leaving the shareholders and trade aghast, perhaps eventually losing the rights to this technology.
Great science and scientists overseen by minor league management = widespread disillusionment and a puny market cap.
We need a respected, powerful, industry savvy, JV partner to help bring on stellar execution, successful commercialization.